Invivyd’s new data highlights Pemgarda’s activity against SARS-CoV-2 XEC and over 75% of variants, with consistent neutralization since Omicron BA.1.
What’s Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
Where Today's News Shapes Tomorrow
